^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lorvotuzumab mertansine (IMGN901)

    i
    Other names: IMGN901, huN901-DM1, BB 10901, IMGN901 TAP, huN901-SPP-DM1
    Company:
    AbbVie
    Drug class:
    Microtubule inhibitor, CD56-targeted antibody-drug conjugate
    Related drugs:
    over2years
    Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. (PubMed, Lung Cancer)
    Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown promising preliminary data in lung cancer with impressive response rates and survival outcomes in previously treated patients.There are several ADCs currently in clinical trials for NSCLC and small cell lung cancer (SCLC). These ADCs often have different targets which include HER2, HER3, TROP2, CEACAM5, and MET in NSCLC and DLL3 in SCLC.Here we review the safety, and efficacy of newer ADCs in lung cancer including ado-trastuzumab emtansine, trastuzumab deruxetecan, patritomab deruxetecan, datopotamab deruxetecan, sacituzumab govitecan, SAR408701, Telisotuzumab vedotin, rovalpituzumab tesirine, lorvotuzumab mertansine, and sacituzumab govitecan.  Several novel methods are underway to improve the safety and efficacy of ADCs which include increasing the drug to antibody ratio (DAR), the potency of the payload, using more innovative payloads and replacing the antibody.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TROP2 (Trophoblast Cell Surface Antigen 2) • CEACAM5 (CEA Cell Adhesion Molecule 5) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Kadcyla (ado-trastuzumab emtansine) • Trodelvy (sacituzumab govitecan-hziy) • tusamitamab ravtansine (SAR408701) • telisotuzumab vedotin (ABBV-399) • Rova-T (rovalpituzumab tesirine) • lorvotuzumab mertansine (IMGN901)
    over2years
    Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (clinicaltrials.gov)
    P2, N=62, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021
    Clinical • Trial completion • Trial completion date
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    |
    lorvotuzumab mertansine (IMGN901)
    over3years
    ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. (PubMed, Cancer)
    Lorvotuzumab mertansine (110 mg/m ) is tolerated in children at the adult recommended phase 2 dose; clinical activity is limited.
    Clinical • P2 data • Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    dexamethasone • lorvotuzumab mertansine (IMGN901)